Nicorandil in the prevention of cardiac damage and type 4A myocardial infarction with planned percutaneous coronary intervention in patients with atherosclerosis of coronary arteries
- Authors: Soboleva G.1, Gostishchev R.1, Rogoza A.1, Kotkina T.1, Samko A.1
-
Affiliations:
- National Medical Research Center of Cardiology
- Issue: Vol 30, No 8 (2019)
- Pages: 53-57
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114019
- ID: 114019
Cite item
Open Access
Access granted
Abstract
To study the possibility of reducing the risk of intraoperative cardiac damage and 4a type myocardial infarction by administering the oral nicorandil in patients with a stable form of coronary artery disease before planned percutaneous coronary intervention.
Full Text
About the authors
G. Soboleva
National Medical Research Center of Cardiology
Email: soboleva_galina@inbox.ru
R. Gostishchev
National Medical Research Center of Cardiology
A. Rogoza
National Medical Research Center of Cardiology
T. Kotkina
National Medical Research Center of Cardiology
A. Samko
National Medical Research Center of Cardiology
References
- Миронова О.Ю. Инфаркт миокарда типа 4а // Тер. арх. - 2014; 9: 102-7
- Zeitouni M., Silvain J., Guedeney P. et al. Periprocedural myocardial infarction and injury in elective coronary stenting // Eur. Heart J. - 2018; 39: 1100-9. DOI: 10.1093/ eurheartj/ehx799.
- Алекян Б.Г., Григорьян А.М., Стаферов А.В. и др. Рентгенэндоваскулярная диагностика и лечение заболеваний сердца и сосудов в Российской Федерации - 2017 год // Эндоваскулярная хирургия. - 2018; 5: 93-240
- Montalescot G., Sechtem U., Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology // Eur. Heart J. - 2013; 34: 2949-3003. doi: 10.1093/eurheartj/eht296.
- Kawai Y., Hisamatsu K., Matsubara H. et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon // Eur. Heart J. - 2009; 30: 765-72. DOI: 10.1093/ eurheartj/ehp077.
- Yang J., Zhang J., Cui W. et al. Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention // Anatolian J. Cardiol. - 2015; 15: 125-31. doi: 10.5152/akd.2014.5207.
- Thygesen K., Alpert J., Jaffe A. et al. Fourth universal definition of myocardial infarction // Eur. Heart J. - 2019; 40: 237-69. doi: 10.1093/eurheartj/ehy462.
- Hausenloy D., Yellon D. Preconditioning and postconditioning: underlying and clinical application // Atherosclerosis. - 2009; 204: 334-41. DOI: 10.1016/j. atherosclerosis.2008.10.029.
- Hirohata A., Yamamoto K., Hirose E. et al. Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study // EuroIntervention. - 2014; 9: 1050-6. DOI: 10.4244/ EIJV9I9A178.
- Pang Z., Zhao W., Yao Z. Cardioprotective Effects of Nicorandil on Coronary Heart Disease Patients Undergoing Elective Percutaneous Coronary Intervention // Med. Sci. Monit. - 2017; 23: 2924-30. doi: 10.12659/MSM.902324.
- Gudnadottir G., Andersen K., Thrainsdottir I. et al. Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes // Am. Heart J. - 2017; 191: 65-74. DOI: 10.1016/j. ahj.2017.06.014.
Supplementary files
